Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026)

Takeda Pharmaceutical's Retained Earnings history runs 10 years deep, the most recent figure standing at $4.5 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 41.64% year-over-year to $4.5 billion in Q1 2026; TTM through Mar 2026 was $4.5 billion, a 41.64% decrease from a year earlier, with the FY2026 full-year figure at $4.7 billion, down 39.3% from the prior year.
• Retained Earnings fell to $4.5 billion in Q1 2026 per TAK's latest filing, from $7.1 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $12.7 billion in Q1 2022 and bottomed at $4.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is $9.4 billion (2024), against an average of $9.3 billion.
• Across the five-year window, Retained Earnings retreated 3.67% in 2023 and slumped 41.64% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $10.7 billion in 2022, then declined by 11.45% to $9.4 billion in 2023, then declined by 10.14% to $8.5 billion in 2024, then slipped by 16.16% to $7.1 billion in 2025, then slumped by 36.2% to $4.5 billion in 2026.
• Per Business Quant, the three latest TAK Retained Earnings figures stand at $4.5 billion (Q1 2026), $7.1 billion (Q4 2025), and $7.8 billion (Q3 2025).